Paper Details

  1. Home
  2. Paper Details

Long-term use of a new topical formulation containing piroxicam 0.8% and sunscreen: efficacy and tolerability on actinic keratosis. A proof of concept study.

Author: BabinoGraziella, BianchiLuca, CampioneElena, ChimentiSergio, Di PreteMonia, DiluvioLaura, MilaniMassimo, OrlandiAugusto

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Cyclooxygenase (COX) 1 and 2 enzymes are involved in the development of actinic keratosis and non-melanoma skin cancers. This study examines the potential of diclofenac and piroxicam, non-steroidal anti-inflammatory drugs with different COX-1 inhibition activities, as topical treatments for actinic keratosis.
Paper Details　
Original Abstract of the Article :
Cyclooxygenase (COX) 1 and 2 enzyme up-regulation is involved in the pathogenetic process of actinic keratosis (A.K.) and non-melanoma skin cancers. Diclofenac, a non-steroidal anti-inflammatory (N.S.A.I.D.) drug, is used as topical treatment of A.K. Piroxicam is a N.S.A.I.D. characterized by a high...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1080/03007995.2016.1174678

データ提供：米国国立医学図書館（NLM）

Targeting Actinic Keratosis: A New Topical Formulation

The field of [dermatology] is constantly searching for effective treatments for [skin conditions] like [actinic keratosis]. This study evaluates a new [topical formulation] containing [piroxicam 0.8% and sunscreen] for its efficacy and tolerability in treating [actinic keratosis]. This study investigates the role of [cyclooxygenase (COX) 1 and 2 enzyme up-regulation] in the development of [actinic keratosis] and explores the potential of [piroxicam] as a [topical treatment] option.

The study found [that the topical formulation containing piroxicam 0.8% and sunscreen showed promising efficacy and tolerability in treating actinic keratosis]. This is a significant development in the search for effective treatments for this common skin condition.

A New Oasis for Actinic Keratosis Treatment

This study provides a promising new approach to treating [actinic keratosis], offering a potential solution for patients struggling with this condition. The results indicate the potential of [piroxicam] as a valuable tool in the dermatologist's arsenal.

Protecting Your Skin in the Desert Sun

It's crucial to remember that [actinic keratosis] is a condition often associated with excessive sun exposure. Protecting our skin from the sun's harmful rays is essential for maintaining healthy skin. This study reminds us that [topical treatments] can be effective for [skin conditions] like [actinic keratosis].

Dr. Camel's Conclusion

This study offers a ray of hope in the desert of [actinic keratosis] treatment. The development of a new [topical formulation] containing [piroxicam] is a significant step forward, offering a potential solution for patients. This research emphasizes the importance of continued research and development in [dermatology] to find effective treatments for common skin conditions.

Date :
  1. Date Completed 2017-09-28
  2. Date Revised 2022-03-21
Further Info :

Pubmed ID

27046744

DOI: Digital Object Identifier

10.1080/03007995.2016.1174678

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.